SAIFEI XIE^1,2,4, HUI XIE^2,*, JINCAI GUO³, JIN TAN⁴, YULIN YU¹, MINYI ZHANG¹, SHANG WEN¹

BIOCELL, Vol.48, No.4, pp. 591-599, 2024, DOI:10.32604/biocell.2024.046691

Abstract Background: Puerarin (Pue) has been reported to be a natural active ingredient with multiple antifibrotic properties. This work aimed at exploring the function of Pue in oral submucous fibrosis (OSF) treatment. Methods: Human oral mucosa fibroblasts (hOMF) were induced with transforming growth factor beta1 (TGF-β1) and intervened with Pue. Expressions of fibrosis-related markers were analyzed by Western blot and IF staining. Cell viability was characterized by the CCK-8 assay. Expressions of miR-30 family members were quantified by qRT-PCR. The correlation between fibroblast activation protein (FAP) and miR-30 family expression was evaluated by the Pearson correlation coefficient. Bioinformatics prediction and dual-luciferase… More > Graphic Abstract

ZHENGUO SHI^#,*, QIAOYUN WU^#, HAIYAN SHI, SONGTIE YING, LIANG TAO

BIOCELL, Vol.46, No.4, pp. 979-988, 2022, DOI:10.32604/biocell.2022.015345

Abstract NLRP3 inflammasome-mediated cell pyroptosis aggravates the development of cerebral ischemia/reperfusion (I/R) injury, and the aim of this study is to investigate the potential utilization of the Chinese medicine, Puerarin, in treating this disease. Through conducting in vitro and in vivo experiments, the present study illustrated that Puerarin regulated LncRNA double homeobox A pseudogene 8 (DUXAP8)/miR-223-3p axis to inactivate NLRP3-mediated pyroptotic cell death, resulting in the attenuation of I/R injury. Specifically, the cerebral I/R injury in rat models and hypoxia/reoxygenation (H/R) in primary hippocampus neuron (PHN) cells were inducted, which were subsequently exposed to Puerarin treatment. As expected, we validated that… More >